Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Ariosa Dx Q1 Revenues Double, Posts Profit

The story has been updated to clarify Ariosa's earnings per share for the first quarter of 2014.

NEW YORK (GenomeWeb News) – Ariosa Diagnostics' first quarter revenues more than doubled year over year, the company said in an amended Form S-1 on Wednesday.

For the three months ended March 31, revenues shot up to $19.5 million from $9.6 million in the first quarter of 2013 as revenues from its partnership with Laboratory Corporation of America, as well as from international customers, increased, the San Jose, Calif.-based developer of non-invasive prenatal tests said.

Ariosa and LabCorp partnered in 2012 to make Ariosa's Harmony Prenatal Test available in the US and Canada. In the recently completed quarter, LabCorp-related revenues accounted for 62 percent of total revenues, down from 94 percent in the year-ago first quarter. During 2013 Ariosa entered into agreements with an additional unnamed US healthcare provider and with international clinics to offer Harmony, contributing to the year-over-year bump-up in revenues, it said.

Revenues from its international business grew to $6.9 million in Q1 2014 from $583,000 in the year-ago period as test volume grew.

Ariosa posted a profit of $1.1 million for the quarter. The firm did not provide a per-share earnings figure. In an e-mail to GenomeWeb Daily News, a spokesman said that while the company made money, the net income was payable to preferred shareholders "given that they were entitled to an 8 percent dividend."

During the first quarter of 2013, Ariosa had a net loss of $2.5 million, or $1.47 per share.

Its R&D expenses rose 19 percent to $4.3 million from $3.6 million, while its SG&A costs were up 61 percent to $8.2 million from $5.1 million.

Ariosa finished the first quarter with $16.8 million in cash and cash equivalents.

The company filed a preliminary prospectus with the US Securities and Exchange Commission last month for an initial public offering. Ariosa has not yet priced the IPO.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.